-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
-
Summary
-
Biomarin Pharmaceutical Inc quarterly/annual Income Tax Expense (Benefit) history and growth rate from 2010 to 2023.
- Biomarin Pharmaceutical Inc Income Tax Expense (Benefit) for the quarter ending March 31, 2024 was $16.9 M, a 186% increase year-over-year.
- Biomarin Pharmaceutical Inc Income Tax Expense (Benefit) for the twelve months ending March 31, 2024 was $31.9 M, a 5907% increase year-over-year.
- Biomarin Pharmaceutical Inc annual Income Tax Expense (Benefit) for 2023 was $20.9 M, a 161% increase from 2022.
- Biomarin Pharmaceutical Inc annual Income Tax Expense (Benefit) for 2022 was $8.02 M.
- Biomarin Pharmaceutical Inc annual Income Tax Expense (Benefit) for 2021 was -$11.3 M, a 98.8% increase from 2020.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Growth (%)